摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,5-二氟-2-硝基苯酚 | 151414-46-9

中文名称
3,5-二氟-2-硝基苯酚
中文别名
2-硝基-3,5-二氟苯酚
英文名称
3,5-Difluoro-2-nitrophenol
英文别名
——
3,5-二氟-2-硝基苯酚化学式
CAS
151414-46-9
化学式
C6H3F2NO3
mdl
——
分子量
175.092
InChiKey
LIQHPNDCQUCZKL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    46.1-46.5
  • 沸点:
    241.6±35.0 °C(Predicted)
  • 密度:
    1.619±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    66
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 危险品标志:
    Xi
  • 海关编码:
    2908999090
  • 包装等级:
    III
  • 危险类别:
    9
  • 危险性防范说明:
    P261,P264,P270,P272,P273,P280,P301+P312+P330,P302+P352,P305+P351+P338+P310,P333+P313,P391,P501
  • 危险品运输编号:
    3077
  • 危险性描述:
    H302,H315,H317,H318,H410
  • 储存条件:
    室温下,应保存在惰性气体中。

SDS

SDS:cef86827face7e492343059769185f04
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3,5-Difluoro-2-nitrophenol
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3,5-Difluoro-2-nitrophenol
CAS number: 151414-46-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H3F2NO3
Molecular weight: 175.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    新型三嗪作为有效的和选择性的磷酸二酯酶10A抑制剂
    摘要:
    据报道鉴定了抑制PDE10A的高效和口服活性三嗪。新的类似物对PDE10A表现出低纳摩尔效价,对PDE家族的所有其他成员表现出高选择性,并显示出所需的类药物特性。采用基于结构的药物设计方法,我们通过系统地探索PDE10A配体结合口袋的各个子区域,研究了PDE10A抑制剂对其他已知PDE同工型的选择性。对新合成化合物的ADME和药代动力学特性的系统评估已导致设计出具有良好脑通透性和理想药物动力学(t 1/2,生物利用度,清除率)的类药物候选物。化合物66对PDE10A具有很强的效力(IC 50  = 1.4 nM),对其他PDE具有很高的选择性(> 200x),并且在精神病动物模型中有效。MK-801诱导的机能亢进(MED = 0.1 mg / kg)和条件回避反应(CAR; ID 50  = 0.2 mg / kg)的逆转。
    DOI:
    10.1016/j.bmcl.2012.07.076
  • 作为产物:
    描述:
    参考文献:
    名称:
    Chemical compounds
    摘要:
    化合物的结构式(I)其中:A是一个双环杂环芳基,可选地取代一个或多个取代基;B是连接基团A与基团D的连接器基团,包括一个由3个或4个原子组成的连接器,其中每个原子可独立地选择自碳、氧、氮和硫,并可选择地取代一个或多个C1-6烷基基团,或者这些相邻的烷基取代基团中的两个可形成一个环;C是芳基或者一个单环或双环杂环芳基,每个都可选择性地取代;D是一个芳基或杂环芳基,两者均可选择性地取代;R1是氢、C1-5烷基、C1-3烷酰基或C1-3烷氧羰基;R2到R5分别独立选择自氢、C1-6烷基、芳基和含有最多2个氧、硫和氮杂原子的杂环芳基,这些芳基和杂环芳基可选择性地取代为C1-6烷基、C2-6烯基、C2-6炔基、C1-4烷氧基、C1-4烷酰基、C1-6烷基氨基、C1-4烷基C1-6烷氧基、C1-6烷基氨基C1-6烷基、硝基、氰基、卤素基、三氟甲基、羟基、(CH2)pOH,其中p为1或2,—CO2Ra,和—CONRaRb,其中Ra和Rb独立选择自氢和C1-6烷基,或者R2到R5中的两个可结合形成一个由3到7个成员组成的环;R6是一个酸性官能团;r和s各自独立地为0或1,并且r和s不能同时为0;或其药学上可接受的盐或体内可水解衍生物。
    公开号:
    US06441012B1
点击查看最新优质反应信息

文献信息

  • Novel compounds
    申请人:——
    公开号:US20030144267A1
    公开(公告)日:2003-07-31
    The invention provides compounds of general formula (I) wherein Q, R, R 2 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    这项发明提供了一般式(I)的化合物,其中Q、R、R2、R4、R5、R6、R7和R8如规范中所定义,以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的用途。
  • IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES
    申请人:Stange Hans
    公开号:US20100120763A1
    公开(公告)日:2010-05-13
    The invention relates to imidazo[5,1-c][1,2,4]benzotriazine derivatives of formula I: which are inhibitors of phosphodiesterase 2 or 10 useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type 2 diabetes, metabolic syndrome, glucose intolerance, and pain.
    本发明涉及式I的咪唑并[5,1-c][1,2,4]苯并三嗪衍生物:它们是磷酸二酯酶2或10的抑制剂,可用于治疗精神病等中枢神经系统疾病,以及例如肥胖、2型糖尿病、代谢综合征、葡萄糖耐受不良和疼痛。
  • Vanilloid receptor ligands and their use in treatments
    申请人:Wang Hui-Ling
    公开号:US20050176726A1
    公开(公告)日:2005-08-11
    Pyrimidine ethers and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.
    嘌呤醚及含有它们的组合物,用于治疗急性、炎症性和神经痛、牙痛、普通头痛、偏头痛、集群头痛、混合血管和非血管综合症、紧张性头痛、一般炎症、关节炎、风湿病、骨关节炎、炎症性肠道疾病、炎症性眼部疾病、炎症性或不稳定的膀胱疾病、牛皮癣、伴有炎症成分的皮肤问题、慢性炎症症状、炎症性疼痛及相关的过敏性疼痛和触痛、神经痛及相关的过敏性疼痛和触痛、糖尿病性神经病痛、烧灼性疼痛、交感神经维持性疼痛、感觉缺失综合症、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸、泌尿生殖、胃肠或血管区域内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、一般胃肠道紊乱、胃溃疡、十二指肠溃疡、腹泻、由坏死剂引起的胃损伤、毛发生长、血管运动性或过敏性鼻炎、支气管疾病或膀胱疾病。
  • Structure–Activity Relationship Studies of 3- or 4-Pyridine Derivatives of DS-6930
    作者:Tsuyoshi Shinozuka、Tomoharu Tsukada、Kunihiko Fujii、Eri Tokumaru、Yumi Matsui、Satoko Wakimoto、Tsuneaki Ogata、Kazushi Araki、Ryoko Sawamura、Nobuaki Watanabe、Makoto Mori、Jun Tanaka
    DOI:10.1021/acsmedchemlett.8b00645
    日期:2019.3.14
    Derivatization efforts were continued to discover backups for a potent selective PPARγ modulator, DS-6930. In this Letter, the replacement of 2-pyridine ring in DS-6930 with 3- or 4-pyridyl group is reported. As the introduction of substituents on the pyridine ring did not provide potent partial agonists, modifications of benzimidazole ring were explored to discover potent intermediate agonists. 4′-Alkoxy
    继续进行衍生化工作,以发现有效的选择性PPARγ调节剂DS-6930的后备材料。在这封信中,报道了DS-6930中的2-吡啶环被3-或4-吡啶基取代。由于在吡啶环上引入取代基不提供有效的部分激动剂,因此对苯并咪唑环的修饰进行了探索以发现有效的中间激动剂。4'-烷氧基取代的苯并咪唑在体内没有显示出有效的功效,而7'-氟苯并咪唑3g(DS19161384)被发现可导致血浆葡萄糖大量降低,并具有出色的DMPK谱。
  • S-(2-(Acylamino)phenyl) 2,2-dimethylpropanethioates as CETP inhibitors
    作者:Kimiya Maeda、Hiroshi Okamoto、Hisashi Shinkai
    DOI:10.1016/j.bmcl.2004.02.071
    日期:2004.5
    structure of the benzene moiety of S-(2-(acylamino)phenyl) 2,2-dimethylpropanethioates and CETP inhibitory activity were performed. Substituents on the benzene moiety influenced CETP inhibitory activity in a type and position dependent manner, and electron-withdrawing groups at the 4- or 5-position increased the activity. The most potent compound showed 50% inhibition of CETP activity in human plasma at
    研究了S-(2-(酰基氨基)苯基)2,2-二甲基丙硫醇酯的苯部分的结构与CETP抑制活性之间的关系。苯部分上的取代基以类型和位置相关的方式影响CETP抑制活性,并且4或5位的吸电子基团增加了该活性。最有效的化合物在浓度为2 microM的人血浆中显示出对CETP活性的50%抑制。
查看更多